


Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1. (Previously presented): A compound of formula I




wherein

R is $^{11}\text{CH}_3$, $(^3\text{H})_3\text{C}$, $(\text{CH}_2)_n^{123}\text{I}$, $(\text{CH}_2)_n^{76}\text{Br}$ or $(\text{CH}_2)_n^{18}\text{F}$, n being 1, 2, 3 or 4 in free base or acid addition salt form.


Claim 2. (Cancelled)

Claim 3. (Previously presented): A process for the production of a compound of formula I as defined in claim 1, or a salt thereof, comprising the step of

a) for the production of a compound of formula Ia




wherein R_a is respectively $^{11}\text{CH}_3$ or $(^3\text{H})_3\text{C}$, reacting the compound of formula II




with respectively $^{11}\text{CH}_3\text{I}$ or $\text{C}(^3\text{H})_3\text{I}$, in the presence of a base, or

b) for the production of a compound of formula Ib



wherein Rb is respectively $(\text{CH}_2)_n^{18}\text{F}$, $(\text{CH}_2)_n^{123}\text{I}$ or $(\text{CH}_2)_n^{76}\text{Br}$, reacting a compound of formula III



wherein n is as defined in claim 1 and X is OTs or OMs, with respectively $^{18}\text{F}^\ominus$, $^{123}\text{I}^\ominus$ or $^{76}\text{Br}^\ominus$, or reacting the compound of formula II with a compound of formula IV



wherein X and Rb are as defined above,

and recovering the resulting compound of formula I in free base form or in form of an acid addition salt.

Claim 4. (Previously presented): A compound of formula I as defined in claim 1, in free base or acid addition salt form, for use as a marker for neuroimaging.

Claim 5. (Previously presented): A composition for labeling brain and peripheral nervous system structures involving mGlu5 receptors *in vivo* or *in vitro* comprising a compound of formula I as defined in claim 1, in free base or acid addition salt form.

Claim 6. (Previously presented): A method for labeling brain and peripheral nervous system structures involving mGlu5 receptors *in vitro* or *in vivo*, which comprises contacting brain tissue with a compound of formula I as defined in claim 1, in free base or acid salt form.